Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients

American Journal of Nephrology

Volumn 29, Issue 3, 2009, Pages 257-263

  Nishiura, Ryosuke ^a,b   Fujimoto, Shouichi ^a,d   Sato, Yuji ^a   Yamada, Kazuhiro ^a   Hisanaga, Shuichi ^b   Hara, Seiichiro ^a   Nakao, Hiroyuki ^c   Kitamura, Kazuo ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b Koga General Hospital   (Japan)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Aortic calcification index; Cardiovascular events; Hemodialysis patients; Osteoprotegerin; Vascular calcification

Indexed keywords

OSTEOPROTEGERIN;

ADULT; AGED; AORTA DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CALCINOSIS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; YOUNG ADULT;

EID: 51849130273     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000157629     Document Type: Article

References (36)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(suppl 3):S112-S119.
2. Wilson PW, Kauppila LI, O'Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001;103:1529-1534.
3. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
4. Goodman GW, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
5. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002;106:100-105.
6. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-436.
7. Cozzolino M, Mazzaferro S, Pugliese F, Brancaccio D: Vascular calcification and uremia: what do we know? Am J Nephrol 2008;28:339-346.
8. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
9. Block GA, Hulbert-Shearon T, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
10. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-1187.
11. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, Vernejoul M-C: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943-1951.
12. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268.
13. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC: Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 2004;89:4104-4112.
14. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease: osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2002;106:1192-1194.
15. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004;109:2175-2180.
16. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006;47:1850-1857.
17. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H: The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003;42:303-309.
18. Morena M, Terrier N, Jaussent I, Leray-Maragues H, Chalabi L, Rivory JP, Maurice T, Delcourt C, Cristol JP, Canaud B, Dupuy AM: Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262-270.
19. Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, Maekawa K, Yamakawa T, Imanishi Y, Inaba M, Nishizawa Y: Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 2007;49:417-425.
20. Yamada K, Fujimoto S, Nishiura R, Komatsu H, Tatsumoto M, Sato Y, Hara S, Hisanaga S, Ochiai H, Eto T: Risk factors of the progression abdominal aortic calcification in patients on chronic haemodialysis. Nephrol Dial Transplant 2007;22:2032-2037.
21. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154-2169.
22. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
23. Moe SM, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, Meyer CA: Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003;18:1152-1158.
24. Nitta K, Akiba T, Uchida K, Otsubo S, Takei T, Yumura W, Kabaya T, Nihei H: Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;44:1886-1889.
25. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG: Association between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008;23:586-593.
26. Mehrotra R: Disordered mineral metabolism and vascular calcification in nondialysed chronic kidney disease patients. J Ren Nutr 2006;16:100-118.
27. Blacher J, Guerin AP, Marchais SJ, London GM: Arterial calcification, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
28. Spiegel DM, Raggi P, Mehta R, Lindberg JS, Choncho M, Ehrlich J, James G, Chertow GM, Block GA: Coronary and aortic calcifications in patients new to dialysis. Hemodial Int 2004;8:265-272.
29. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM: Increased plasma concentration of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 2003;149:39-42.
30. Collin-Osdoby P: Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;26:1046-1057.
31. Browner WS, Lui L-Y, Cummings SR: Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631-637.
32. Gannagé-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, Trak-Smayra V: Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 2008;158:353-359.
33. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, Westenfeld R, Jahnen-Dechent W, Chen NX: Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005;67:2295-2304.
34. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, Manni M, Morosetti M, Moscaritolo E, Sardella D, Bonucci E, Jankovic L: Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002;17:233-238.
35. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, Zsontsich T, Klaushofer K, Delling G, Oberbauer R: Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002;39:580-586.
36. Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, Kawaguchi Y, Gejyo F, Kurokawa K, Fukagawa M: Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002;39:525-532.